PPD Phase 1
Austin, Texas, 78744, United States
NCT Number: NCT01791049
TD-1607, administered intravenously as single doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Phase 1
Austin, Texas, 78744, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 11 days
Adverse events, laboratory abnormalities, ECGs, and vital sign measurements.
Time frame: 96 hours
Cmax, Tmax, AUC0-t, AUC0-24, AUCinf, CL, Vdss, t1/2, amount excreted in urine (Ae), fraction eliminated in urine (fe), and CLr.
Theravance Biopharma
Industry
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1607, a Glycopeptide-Cephalosporin Heterodimer Gram-Positive Antibiotic, in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02992951
Bacterial Infections, Bacterial Infections and Mycoses
Hull, East Riding of Yorkshire, United Kingdom
View Trial DetailsNCT06548841
Bacterial Infections, Bacterial Infections and Mycoses
Bologna, Italy
View Trial DetailsNCT02284126
Bacterial Infections, Bacterial Infections and Mycoses
New York, United States
View Trial DetailsNCT07122596
Bacterial Infection, Bacterial Infections
Karachi, Sindh, Pakistan
View Trial Details